Vexim SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Edison Investment Research
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
CLINICAL BIOMECHANICS Publishes Study Proving Positive Performance of Vexim SA's SpineJack-DJ
Dow Jones reported that Vexim SA announced that the results of a comparative biomechanical study carried out by Marburg University's Traumatology department (Germany) were published in the August issue of the CLINICAL BIOMECHANICS international journal. The aim of this study was to evaluate the anatomic restoration of 36 fractured vertebral bodies with osteoporosis and the maintaining of the gained height after recompression by comparing the Company's SpineJack and balloon kyphoplasty techniques. The results obtained demonstrate an advantage in favor of the SpineJack regarding the restoration of vertebral height that is carried out to reestablish the spinal column's balance.
Latest Developments for Vexim SA
- Vexim SA announces results of study of SpineJack
- Vexim SA Announces Results of Retrospective Study of SpineJack
- Vexim SA Announces Preliminary Results of International Clinical Study on Performance of SpineJack in Treating Vertebral Fractures
- Vexim SA Accelerates European Development and Establishes Subsidiary in Spain
Latest Key Developments in Medical
- Share this
- Digg this